We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 21, 2020

Minimal Activity of Single-Agent Nivolumab in Relapsed/Refractory Follicular Lymphoma



Additional Info

Disclosure statements are available on the authors' profiles:

Efficacy and Safety Results From CheckMate 140, a Phase 2 Study of Nivolumab for Relapsed/Refractory Follicular Lymphoma
Blood 2020 Aug 31;[EPub Ahead of Print], P Armand, AMH Janssens, G Gritti, et al

Further Reading